DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Altoprev (Lovastatin) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

ALTOPREV®

ALTOPREV® Clinical Studies

In clinical studies with ALTOPREV®, adverse reactions have generally been mild and transient. In controlled studies with 467 patients who received ALTOPREV®, <3% of patients were discontinued due to adverse experiences attributable to ALTOPREV®. This was similar to the discontinuation rate in the placebo and lovastatin immediate-release treatment groups. Pooled results from clinical studies with ALTOPREV® show that the most frequently reported adverse reactions in the ALTOPREV® group were infection, headache and accidental injury. Similar incidences of these adverse reactions were seen in the lovastatin and placebo groups. The most frequent adverse events thought to be related to ALTOPREV® were nausea, abdominal pain, insomnia, dyspepsia, headache, asthenia, and myalgia. In controlled trials (e.g., vs. placebo and vs. lovastatin immediate-release), clinical adverse experiences reported as 5% in any treatment group are shown in Table VII below.

Table VII Pooled Controlled Studies TESS by Body System and COSTART Term, Most Common (5% in Any Group)
Treatment
Placebo ALTOPREV® MEVACOR®
Randomized Patients, n=34467329
Body SystemCOSTART Term
Body as a WholeInfection3 (9)52 (11)52 (16)
Accidental Injury3 (9)26 (6)12 (4)
Asthenia2 (6)12 (3)6 (2)
Headache2 (6)34 (7)26 (8)
Back Pain1 (3)23 (5)18 (5)
Flu Syndrome1 (3)24 (5)18 (5)
Pain014 (3)17 (5)
DigestiveDiarrhea2 (6)15 (3)8 (2)
MusculoskeletalArthralgia2 (6)24 (5)20 (6)
Myalgia5 (15)14 (3)11 (3)
NervousDizziness2 (6)10 (2)5 (2)
RespiratorySinusitis1 (3)17 (4)20 (6)
UrogenitalUrinary Tract Infection2 (6)8 (2)9 (3)

Lovastatin Immediate-Release

Lovastatin Immediate-Release Phase III Clinical Studies

In Phase III controlled clinical studies involving 613 patients treated with lovastatin immediate-release, the adverse experience profile was similar to that shown below for the 8,245-patient EXCEL study [see Expanded Clinical Evaluation of Lovastatin (EXCEL) Study ]. Persistent increases of serum transaminases have been noted (see WARNINGS, Liver Dysfunction). About 11% of patients had elevations of CK levels of at least twice the normal value on one or more occasions. The corresponding values for the control agent cholestyramine was 9%. This was attributable to the noncardiac fraction of CK. Large increases in CK have sometimes been reported (see WARNINGS, Myopathy/Rhabdomyolysis).

Expanded Clinical Evaluation of Lovastatin (EXCEL) Study

Lovastatin immediate-release was compared to placebo in 8,245 patients with hypercholesterolemia [Total-C 240-300 mg/dL (6.2-7.8 mmol/L)] in the randomized, double-blind, parallel, 48-week EXCEL study. Clinical adverse experiences reported as possibly, probably or definitely drug-related in ≥1% in any treatment group are shown in the table below. For no event was the incidence on drug and placebo statistically different.

Table VIII Clinical Adverse Events Reported as Possibly, Probably or Definitely Drug-Related in ≥1% in Any Treatment Group in the EXCEL Study
Placebo

(N=1663)
%
Lovastatin IR
20 mg q.p.m.
(N=1642)
%
Lovastatin IR
40 mg q.p.m.
(N=1645)
%
Lovastatin IR
20 mg b.i.d.
(N=1646)
%
Lovastatin IR
40 mg b.i.d.
(N=1649)
%
Body As a Whole
   Asthenia1.41.71.41.51.2
Gastrointestinal
   Abdominal pain1.62.02.02.22.5
   Constipation1.92.03.23.23.5
   Diarrhea2.32.62.42.22.6
   Dyspepsia1.91.31.31.01.6
   Flatulence4.23.74.33.94.5
   Nausea2.51.92.52.22.2
Musculoskeletal
   Muscle cramps0.50.60.81.11.0
   Myalgia1.72.61.82.23.0
Nervous System/Psychiatric
   Dizziness0.70.71.20.50.5
   Headache2.72.62.82.13.2
Skin
   Rash0.70.81.01.21.3
Special Senses
   Blurred vision0.81.10.90.91.2

Other clinical adverse experiences reported as possibly, probably or definitely drug-related in 0.5% to 1.0% of patients in any drug-treated group are listed below. In all these cases the incidence on drug and placebo was not statistically different. Body as a Whole: chest pain; Gastrointestinal: acid regurgitation, dry mouth, vomiting; Musculoskeletal: leg pain, shoulder pain, arthralgia; Nervous System/Psychiatric: insomnia, paresthesia; Skin: alopecia, pruritus; Special Senses: eye irritation.

In the EXCEL study (see CLINICAL PHARMACOLOGY, Clinical Studies), 4.6% of the patients treated up to 48 weeks were discontinued due to clinical or laboratory adverse experiences which were rated by the investigator as possibly, probably or definitely related to therapy with lovastatin immediate-release. The value for the placebo group was 2.5%.

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS)

In AFCAPS/TexCAPS (see CLINICAL PHARMACOLOGY, Clinical Studies) involving 6,605 participants treated with 20-40 mg/day of lovastatin immediate-release (n=3,304) or placebo (n=3,301), the safety and tolerability profile of the group treated with lovastatin immediate-release was comparable to that of the group treated with placebo during a median of 5.1 years of follow-up. The adverse experiences reported in AFCAPS/TexCAPS were similar to those reported in EXCEL [see ADVERSE REACTIONS, Expanded Clinical Evaluation of Lovastatin (EXCEL) Study ].

Concomitant Therapy

In controlled clinical studies in which lovastatin immediate-release was administered concomitantly with cholestyramine, no adverse reactions peculiar to this concomitant treatment were observed. The adverse reactions that occurred were limited to those reported previously with lovastatin or cholestyramine. Other lipid-lowering agents were not administered concomitantly with lovastatin during controlled clinical studies. Preliminary data suggests that the addition of gemfibrozil to therapy with lovastatin is not associated with greater reduction in LDL-C than that achieved with lovastatin alone. In uncontrolled clinical studies, most of the patients who have developed myopathy were receiving concomitant therapy with cyclosporine, gemfibrozil or niacin (nicotinic acid) (see WARNINGS, Myopathy/Rhabdomyolysis).

The following effects have been reported with drugs in this class. Not all the effects listed below have necessarily been associated with lovastatin therapy.

Skeletal: muscle cramps, myalgia, myopathy, rhabdomyolysis, arthralgias.

Neurological: dysfunction of certain cranial nerves (including alteration of taste, impairment of extra-ocular movement, facial paresis), tremor, dizziness, vertigo, memory loss, paresthesia, peripheral neuropathy, peripheral nerve palsy, psychic disturbances, anxiety, insomnia, depression.

Hypersensitivity Reactions: An apparent hypersensitivity syndrome has been reported rarely which has included one or more of the following features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.

Gastrointestinal: pancreatitis, hepatitis, including chronic active hepatitis, cholestatic jaundice, fatty change in liver; and rarely, cirrhosis, fulminant hepatic necrosis, and hepatoma; anorexia, vomiting.

Skin: alopecia, pruritus. A variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails) have been reported.

Reproductive: gynecomastia, loss of libido, erectile dysfunction.

Eye: progression of cataracts (lens opacities), ophthalmoplegia.

Laboratory Abnormalities: elevated transaminases, alkaline phosphatase, γ-glutamyl transpeptidase, and bilirubin; thyroid function abnormalities.

Drug label data at the top of this Page last updated: 2008-08-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012